Health News (Reuters)

Teva Pharm overhauls structure and top management

TEL AVIV (Reuters) - Teva Pharmaceutical Industries is streamlining its company structure and making sweeping changes to senior management as part of an overhaul it hopes will please investors worried about the company's massive debt.

Biogen boosts multiple sclerosis holding with Alkermes license

(Reuters) - Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Regeneron drops eye-drug combination as Novartis chases Eylea

(Reuters) - Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

Rising Chinese ozone levels cause higher mortality: study

SHANGHAI (Reuters) - Rising ozone pollution in China's cities has emerged as a major health risk, causing a rise in deaths from strokes and heart disease among vulnerable residents, according to a new study by a team of Chinese researchers.